Operose Advisors’s United Therapeutics UTHR Stock Holding History

Operose Advisors’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-2	Closed	-$1.19K	–	683
2026 Q1	$1.19K	Buy	+2	New	+$996	﹤0.01%	529

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Norges Bank Oslo, Norway $1T AUM

Operose Advisors's UTHR Position: Q2 2026 in Review

Operose Advisors sold out of United Therapeutics (UTHR) in Q2 2026, closing a stake of 2 shares — an estimated $1.19K sold.

Operose Advisors first reported a position in UTHR in Q1 2026 and held it in 1 quarter. The position peaked at $1.19K in Q1 2026. 884 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

Operose Advisors reported no remaining United Therapeutics position as of Q2 2026 after selling out during the quarter.
Operose Advisors sold 2 United Therapeutics shares in Q2 2026, an estimated $1.19K.
Operose Advisors first reported a position in United Therapeutics in Q1 2026 and held it in 1 quarter.
Operose Advisors's United Therapeutics position peaked at $1.19K in Q1 2026.
884 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Operose Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.